Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer.

Binnemars-Postma K, Bansal R, Storm G, Prakash J.

FASEB J. 2018 Feb;32(2):969-978. doi: 10.1096/fj.201700629R. Epub 2018 Jan 3.

PMID:
29066614
2.

SJSZ glycoprotein (38 kDa) modulates macrophage type 1/2-related factors at hepatocarcinogenic stage in N-nitrosodiethylamine-treated Balb/c.

Lee J, Lim KT.

Mol Cell Biochem. 2013 Jan;372(1-2):17-26. doi: 10.1007/s11010-012-1441-5. Epub 2012 Sep 7.

PMID:
22956448
3.

Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders.

Zigmond E, Preston S, Pappo O, Lalazar G, Margalit M, Shalev Z, Zolotarov L, Friedman D, Alper R, Ilan Y.

Gut. 2007 Jan;56(1):82-9.

4.

Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.

Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK.

J Immunol. 2002 Nov 15;169(10):5796-804.

5.

Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.

Ostrand-Rosenberg S, Grusby MJ, Clements VK.

J Immunol. 2000 Dec 1;165(11):6015-9.

Supplemental Content

Loading ...
Support Center